In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer. Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug interactions, and their personal experiences with managing adverse effects in their patients. Finally, the discussion turns to methods for promoting treatment adherence and persistence and briefly touches on insurance coverage and affordability, including ways that patients and providers can work together to ensure access to approved oral SERDs.Presenters:Manali Bhave, MDPhase I Medical DirectorAssistant ProfessorDepartment of Hematology & Medical OncologyWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaAnnalise Labatut, PharmD, BCOPOncology Clinical Pharmacy Specialist – Breast OncologyEmory Healthcare/Winship Cancer InstituteAtlanta, GeorgiaJamie L. Carroll, CNP, APRN, MSNAssistant Professor of Medical OncologyMayo ClinicRochester, MinnesotaLink to the full program:https://bit.ly/3UT5Be8Claim CME Credit:https://bit.ly/4dBuxhx

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related